A TRIAL TO COMPARE THE INJECTION SITE PAIN EXPERIENCE OF SEMAGLUTIDE 0.25 MG AND DULAGLUTIDE 0.75 MG ADMINISTERED SC
- Conditions
- Diabetes10018424
- Registration Number
- NL-OMON48004
- Lead Sponsor
- ovo Nordisk A/S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 104
- Male or female, aged 18-75 years (both inclusive) at the time of signing
informed consent.
- Body mass index >=25.0 kg/m2.
- Considered to be generally healthy based on the medical history, physical
examination, and the results of vital signs, electrocardiogram and clinical
laboratory tests performed during the screening visit, as judged by the
Investigator.
- Female who is pregnant, breast-feeding or intends to become pregnant within 4
weeks of Day 1 or is of childbearing potential and not using highly effective
contraceptive methods.
- Any disorder which in the Investigator*s opinion might jeopardise subject*s
safety, evaluation of results, or compliance with the protocol.
- Glycosylated hemoglobin (HbA1c) >= 6.5 % (48 mmol/mol) at screening.
- Use of prescription medicinal products or non-prescription drugs or herbal
products, except routine vitamins, topical medication, contraceptives and
occasional use of paracetamol (not allowed within 24 hours prior to drug
administration), within 14 days prior to Day 1.
- Average intake of more than 21 units of alcohol per week for male subjects
and more than 14 units per week for female subjects: 1 unit of alcohol equals
approximately 250 mL of beer, 100 mL of wine, or 35 mL of spirits).
- Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines
[including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic
antidepressants, and alcohol) at screening and admission to the clinical
research.
- Use of tobacco and nicotine products, defined as any of the below:
o Smoking more than 1 cigarette or the equivalent per day on average.
o Not able or willing to refrain from smoking and use of nicotine substitute
products during the in-house period.
- Subject is not able to understand and read English or Dutch, or subject is
not able to understand and comply with the study requirements.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Intensity of injection site pain</p><br>
- Secondary Outcome Measures
Name Time Method <p>Exploratory endpoints:<br /><br>Categorical assessment of injection site pain<br /><br>More than moderate injection site pain<br /><br>Quality of pain<br /><br>Duration of pain<br /><br>Comparative pain experience</p><br>